Institutional dossier
The documented history of Eli Lilly and Company: chronology, people, research, capital and compute, and governance. Every statement opens its source and its limits.
Records dated 2024-01-07 to 2026-01-12 · 0 undated
4 claims · 4 sources · 4 not editorially accepted. The counts describe this selection. They do not measure completeness or independent confirmation.
Scope, evidence and limits
Description: Pharmaceutical company; partner named in Isomorphic Labs' and NVIDIA's releases.
The records are grouped automatically. No human inspection of the selected claims, source paths or framing is recorded for this dossier. Each source passage shows how it was checked.
The dossier is computed from existing records. It is not a continuous history of the institution, and a missing record does not mean that an event or relationship did not happen. The chronology uses the dates of events and reports, not the date the public could first have known of them. Later sources can describe earlier events.
Select any statement to see its exact claim, qualification, date note, evidence passage, location in the source, source version and review status. The description above is Selekoa’s stored description of the institution, based on these sources:
- insitro and Lilly Enter Strategic Agreements to Advance Novel Treatments for Metabolic Diseases
- XtalPi Holdings Limited: Voluntary Announcement - XtalPi Subsidiary Ailux Announces Strategic Collaboration with Lilly to Advance (AI Driven) Bispecific Antibody Development
- Isomorphic Labs announces strategic multi-target research collaboration with Lilly
Chronology
Records about the institution itself and documented changes to its frameworks, by year. Expand a year to read the claims. People’s other institutional records and related documents have their own sections. Where a date gives only the year or month, the order within it is unknown.
2024Record year · 2 claims
- Isomorphic Labs announced on 7 January 2024 a strategic research collaboration with Eli Lilly and Company to discover small-molecule therapeutics against multiple targets, stating an upfront cash payment of $45 million and eligibility for up to $1.7 billion in performance-based milestone payments.Isomorphic Labs → announced a partnership with → Eli Lilly and CompanyInspect claim & evidence ↗
Record about this institution · Stated in source · Supported Announced
Activity: announced · Stage: announced · exact USD 45,000,000 · transaction
Qualification and date notes
Announced terms as Isomorphic Labs states them. The milestone figure is an "up to" eligibility, excluded from the upfront and royalties, and is not a payment received; no programme outcome is implied. The release calls this Isomorphic's "first pharmaceutical partnership" (its own words).
Dated by the release.
- insitro announced on 9 October 2024 three strategic agreements with Eli Lilly and Company on potential new medicines for metabolic diseases.insitro → announced a partnership with → Eli Lilly and CompanyInspect claim & evidence ↗
Record about this institution · Stated in source · Supported Announced
Activity: announced
Qualification and date notes
An announced arrangement; the release discloses no amounts in the passage quoted, and the record does not establish that any programme reached the clinic.
Date of insitro's release.
2025Record year · 1 claims
- XtalPi announced on 5 November 2025 that its wholly-owned subsidiary Shanghai Ailux Biotechnology entered a strategic platform-based collaboration with Eli Lilly and Company on bispecific antibodies, with a total potential value of up to US$345 million.Ailux → announced a partnership with → Eli Lilly and CompanyInspect claim & evidence ↗
Record about this institution · Stated in source · Supported Announced
Activity: announced
Qualification and date notes
Announced terms as XtalPi states them; "up to" is conditional on milestones and is not a payment. The upfront and near-term amounts are stated only as "tens of millions US dollars".
Date of the HKEXnews listing of XtalPi's announcement.
2026Record year · 1 claims
- NVIDIA's 12 January 2026 release states that Lilly announced a collaboration with NVIDIA to launch a co-innovation lab on drug discovery, describing the initiative as "representing a total investment of up to $1 billion expected in talent, infrastructure and compute over five years".NVIDIA → announced a partnership with → Eli Lilly and CompanyInspect claim & evidence ↗
Record about this institution · Stated in source · Supported Announced
Activity: announced
Qualification and date notes
An announced collaboration. The "up to $1 billion" is an expected total over five years as stated, not a payment, and the release does not allocate it between the companies; the release's own phrase "first-of-its-kind" is not adopted. The “up to” figure stays in the statement and is not recorded as an amount (maintainer decision of 2026-10-30).
Dated by the release.